New drug RC288 targets Hard-to-Treat tumors in early trial
NCT ID NCT07537881
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests a new drug called RC288 in people with advanced solid tumors that cannot be removed by surgery or have spread. The main goals are to check safety, find the best dose, and see if it shrinks tumors. About 326 adults aged 18 to 75 with good overall health will take part. This is an early-phase trial, so the drug is not yet proven to work.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for LOCALLY ADVANCED UNRESECTABLE OR METASTATIC MALIGNANT SOLID TUMOR are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Hunan Cancer Hospital
Changsha, Hunan, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Spinal injection of dual immunotherapy plus chemotherapy targets cancer spread to brain lining
- Lab-Made immune protein takes on advanced cancers in first human test
- Blood test may let cancer patients take safe breaks from immunotherapy
- Engineered immune cells take on Hard-to-Treat cancers
- Experimental cell therapy takes aim at Hard-to-Treat cancers
- Could simple Over-the-Counter drugs supercharge cancer immunotherapy?